We are live on ! Find out more
CCM

Catalio Capital Management Portfolio holdings

AUM $479M
1-Year Est. Return 140.7%
This Fund
S&P 500
This Quarter Est. Return
+56.58%
1 Year Est. Return
+140.7%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$541M
AUM Growth
+$64M
Cap. Flow
-$9.38M
Cap. Flow %
-1.73%
Top 10 Hldgs %
55.94%
Holding
50
New
10
Increased
10
Reduced
13
Closed
12

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$31.5M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$20M
3
EXAS
Exact Sciences
EXAS
+$12.4M
4
SUPN icon
Supernus Pharmaceuticals
SUPN
+$11.6M
5
IRON icon
Disc Medicine
IRON
+$11.1M

Top Sells

Rank Stock Value
1
EW icon
Edwards Lifesciences
EW
+$30.6M
2
GILD icon
Gilead Sciences
GILD
+$25.2M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$19.6M
4
CORT icon
Corcept Therapeutics
CORT
+$17.6M
5
BBIO icon
BridgeBio Pharma
BBIO
+$14.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
1
Eli Lilly
LLY
$1.07T
$43.8M 8.09%
57,376
+3,460
+6% +$2.57M
ABBV icon
2
AbbVie
ABBV
$458B
$35.9M 6.63%
+154,834
New +$31.5M
BBIO icon
3
BridgeBio Pharma
BBIO
$16.5B
$32.3M 5.98%
622,729
-304,982
-33% -$14.9M
ISRG icon
4
Intuitive Surgical
ISRG
$121B
$31.9M 5.9%
71,343
+14,669
+26% +$7.04M
ASND icon
5
Ascendis Pharma A/S
ASND
$16.7B
$28.8M 5.33%
144,954
-34,972
-19% -$6.52M
SLNO
6
DELISTED
Soleno Therapeutics
SLNO
$28.3M 5.23%
418,245
+8,301
+2% +$615K
DNTH icon
7
Dianthus Therapeutics
DNTH
$5.68B
$26.3M 4.86%
667,615
-78,912
-11% -$2.02M
BSX icon
8
Boston Scientific
BSX
$65.8B
$25.7M 4.75%
262,972
+33,926
+15% +$3.51M
SNDX icon
9
Syndax Pharmaceuticals
SNDX
$1.84B
$24.8M 4.59%
1,614,717
-489,795
-23% -$6.41M
CYTK icon
10
Cytokinetics
CYTK
$11B
$24.8M 4.59%
451,581
-149,858
-25% -$6.17M
NTRA icon
11
Natera
NTRA
$37.5B
$23.9M 4.42%
148,369
+51,072
+52% +$8.08M
REGN icon
12
Regeneron Pharmaceuticals
REGN
$68.8B
$19.9M 3.67%
+35,344
New +$20M
GPCR icon
13
Structure Therapeutics
GPCR
$3.49B
$18.3M 3.37%
651,810
-18,765
-3% -$374K
QURE icon
14
uniQure
QURE
$2.68B
$16.5M 3.05%
282,940
-134,503
-32% -$2.44M
IRON icon
15
Disc Medicine
IRON
$2.83B
$14.3M 2.65%
216,527
+185,866
+606% +$11.1M
ABVX
16
Abivax
ABVX
$11B
$13.8M 2.54%
+162,141
New +$9.94M
SUPN icon
17
Supernus Pharmaceuticals
SUPN
$2.68B
$13.7M 2.54%
+287,090
New +$11.6M
EXAS
18
DELISTED
Exact Sciences
EXAS
$13.6M 2.52%
+248,987
New +$12.4M
PHAT icon
19
Phathom Pharmaceuticals
PHAT
$912M
$13.3M 2.46%
1,128,521
+456,231
+68% +$4.71M
ADPT icon
20
Adaptive Biotechnologies
ADPT
$3.56B
$13.2M 2.45%
884,890
-511,555
-37% -$6.23M
RNAM
21
DELISTED
Avidity Biosciences
RNAM
$11.5M 2.12%
+263,256
New +$10.6M
ADMA icon
22
ADMA Biologics
ADMA
$1.92B
$10M 1.86%
684,508
+114,804
+20% +$1.97M
RARE icon
23
Ultragenyx Pharmaceutical
RARE
$2.65B
$8.76M 1.62%
291,262
+77,860
+36% +$2.33M
GUTS icon
24
Fractyl Health
GUTS
$123M
$8.29M 1.53%
5,214,236
+5,000,000
+2,334% +$6.49M
GRAL
25
GRAIL Inc
GRAL
$2.91B
$8.16M 1.51%
+137,928
New +$5.27M
1
2

Similar funds

FFG
Frisch Financial Group Melville, New York $478M AUM 16.28% 1-Year Est. Return
RFWA
RPg Family Wealth Advisory Burlington, Massachusetts $479M AUM 25.83% 1-Year Est. Return
SWM
Silverlake Wealth Management Williston, Vermont $479M AUM 17.75% 1-Year Est. Return
CMI
Clare Market Investments Dallas, Texas $478M AUM
TCM
Towneley Capital Management Laguna Hills, California $478M AUM 16.21% 1-Year Est. Return
LIM
Longfellow Investment Management Boston, Massachusetts $480M AUM 8% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return
YLHM
Yelin Lapidot Holdings Management Tel Aviv, Israel $480M AUM 42.17% 1-Year Est. Return

Catalio Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Catalio Capital Management held 50 positions worth $541M, up 13% from $477M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Catalio Capital Management's Q3 2025 filing shows 10 new, 10 increased, 13 reduced and 12 closed positions. Its largest new stake was AbbVie: 154,834 shares worth $35.9M. The largest sale was Edwards Lifesciences, an estimated $30.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Catalio Capital Management's largest Q3 2025 buy was AbbVie: 154,834 shares worth $35.9M.
  • Catalio Capital Management added most to Disc Medicine in Q3 2025, an estimated $11.1M increase.
  • Catalio Capital Management's biggest Q3 2025 reduction was BridgeBio Pharma, cutting an estimated $14.9M.
  • Catalio Capital Management fully exited Edwards Lifesciences in Q3 2025, selling an estimated $30.6M.
  • Catalio Capital Management's ten largest holdings make up 56% of its $541M portfolio in Q3 2025.
  • Catalio Capital Management opened 10 new positions and closed 12 in Q3 2025.
  • Catalio Capital Management's portfolio value rose 13% quarter-over-quarter to $541M.

Based on Catalio Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.